Novavax, Inc.
NVAX
$9.02
$0.53986.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.22% | 25.92% | -30.65% | -15.68% | -38.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.22% | 25.92% | -30.65% | -15.68% | -38.17% |
| Cost of Revenue | -41.77% | -42.87% | -45.56% | -39.55% | -54.97% |
| Gross Profit | 193.26% | 611.28% | 421.66% | 226.47% | 278.22% |
| SG&A Expenses | -47.45% | -31.62% | -28.65% | -12.48% | -7.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.06% | -39.45% | -40.47% | -29.28% | -42.40% |
| Operating Income | 228.18% | 211.92% | 57.97% | 52.62% | 53.42% |
| Income Before Tax | 249.33% | 223.49% | 67.48% | 49.22% | 50.66% |
| Income Tax Expenses | 56.89% | 215.82% | 435.89% | 367.24% | 335.94% |
| Earnings from Continuing Operations | 243.65% | 220.06% | 65.60% | 48.11% | 49.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 243.65% | 220.06% | 65.60% | 48.11% | 49.84% |
| EBIT | 228.18% | 211.92% | 57.97% | 52.62% | 53.42% |
| EBITDA | 269.48% | 240.20% | 64.07% | 57.66% | 58.47% |
| EPS Basic | 198.02% | 198.04% | 77.62% | 65.76% | 62.96% |
| Normalized Basic EPS | 193.35% | 199.26% | 74.18% | 66.85% | 63.27% |
| EPS Diluted | 182.66% | 183.85% | 76.09% | 64.56% | 61.93% |
| Normalized Diluted EPS | 175.98% | 181.47% | 72.55% | 65.58% | 62.22% |
| Average Basic Shares Outstanding | 24.83% | 37.98% | 51.15% | 59.44% | 54.49% |
| Average Diluted Shares Outstanding | 26.69% | 40.90% | 50.02% | 57.84% | 52.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |